Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vivos Therapeutics, Inc. - SIC # 8081 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VVOS
Nasdaq
8081
www.vivos.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vivos Therapeutics, Inc.
Best Momentum Stocks to Buy for January 8th
- Jan 8th, 2025 3:15 pm
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Dec 23rd, 2024 1:00 pm
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy
- Dec 18th, 2024 5:00 pm
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 17th, 2024 12:44 pm
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
- Nov 15th, 2024 9:00 am
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
- Nov 14th, 2024 9:05 pm
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
- Nov 13th, 2024 10:00 pm
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
- Oct 8th, 2024 11:30 am
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- Sep 19th, 2024 11:00 am
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
- Sep 18th, 2024 2:05 pm
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
- Sep 18th, 2024 11:00 am
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
- Aug 14th, 2024 8:05 pm
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
- Aug 14th, 2024 11:30 am
Vivos eyes human trials for radiation treatment gel with IDE submission
- Jul 1st, 2024 4:33 pm
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
- Jun 27th, 2024 11:30 am
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
- Jun 12th, 2024 11:30 am
Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors
- May 20th, 2024 5:04 pm
Vivos Therapeutics Inc (VVOS) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
- May 15th, 2024 5:01 pm
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
- May 14th, 2024 8:05 pm
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
- May 14th, 2024 11:30 am
Scroll